BACKGROUND: After vaginal surgery, oral and parenteral narcotics are used commonly for @entity158 relief, and their use may exacerbate the incidence of sedation, @entity390 , and @entity391 , which ultimately delays convalescence. Previous studies have demonstrated that rectal analgesia after surgery results in lower @entity158 scores and less intravenous @entity1286 consumption. @entity14703 and @entity15149 rectal suppositories may be used to relieve @entity158 and minimize side effects; however, their efficacy has not been confirmed. OBJECTIVE: We aimed to evaluate the use of @entity14703 and @entity15149 suppositories for @entity158 reduction in vaginal surgery. MATERIALS AND METHODS: A prospective, randomized, double-blind, placebo-controlled trial that used @entity14703 and @entity15149 suppositories after inpatient or outpatient vaginal surgery was conducted. Vaginal surgery was defined as (1) vaginal hysterectomy with uterosacral ligament suspension or (2) posthysterectomy prolapse repair that included uterosacral ligament suspension and/or colporrhaphy. @entity14703 and @entity15149 16A (16.2/60 mg) or placebo suppositories were administered rectally immediately after surgery and every 8 hours for a total of 3 doses. @entity1 -reported @entity158 data were collected with the use of a visual analog scale (at 2, 4, 12, and 20 hours postoperatively. Opiate use was measured and converted into parenteral @entity1286 equivalents. The primary outcome was @entity158 , and secondary outcomes included @entity158 medication, antiemetic medication, and a quality of recovery questionnaire. Adverse effects were surveyed at 24 hours and 7 days. Concomitant procedures for @entity322 or pelvic organ prolapse did not preclude enrollment. RESULTS: Ninety @entity1 were randomly assigned consecutively at a single institution under the care of a fellowship-trained surgeon group. Demographics did not differ among the groups with mean age of 55 years, procedure time of 97 minutes, and prolapse at 51%. @entity282 scores were equivalent among both groups at each time interval. The @entity14703 and @entity15149 group used a mean of 57 mg @entity1286 compared with 66 mg for placebo (P=.43) in 24 hours. @entity1 satisfaction with recovery was similar (P=.59). Antiemetic and @entity6058 use were comparable among groups. Subgroup analyses of @entity1 with prolapse and @entity1 <50 years old did not reveal differences in @entity158 scores. The use of @entity14703 and @entity15149 suppositories was uncomplicated, and adverse effects, which included @entity1142 and urinary retention, were similar among groups. CONCLUSION: @entity14703 and @entity15149 suppositories are safe for use after vaginal surgery. @entity14703 and @entity15149 suppositories did not reveal lower @entity158 or substantially lower narcotic use. Further investigation may be warranted to identify a population that may benefit optimally from @entity14703 and @entity15149 use.

Randomized clinical trial of postoperative XXXX and @entity15149 rectal suppositories in vaginal surgery.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Patient'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity322 :: ('MESH:D014549', 'Disease') :: ['urinary incontinence'] @entity14703 :: ('33113', 'Species') :: ['belladonna', 'Belladonna'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity15149 :: ('MESH:D009892', 'Chemical') :: ['opium'] @entity6058 :: ('MESH:D020910', 'Chemical') :: ['ketorolac'] @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity1142 :: ('MESH:D003248', 'Disease') :: ['constipation'] @entity282 :: ('MESH:D010149', 'Disease') :: ['Postoperative pain']
@entity14703 :: (33113,Species) :: ['belladonna']
